A Phase 2 Clinical Trial of TQB2102 for Injection in the Treatment of Patients With Recurrent/Metastatic Advanced Gynecological Tumors to Evaluate the Safety and Efficacy
Latest Information Update: 13 Feb 2025
Price :
$35 *
At a glance
- Drugs TQB 2102 (Primary)
- Indications Gynaecological cancer
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group; Nanjing Shunxin Pharmaceutical
- 04 Feb 2025 New trial record